Warts constitute the commonest cutaneous manifestation of human papillomavirus (HPV) infection. Intralesional Candida antigen immunotherapy is used for wart treatment especially with resistant cases. Objective: To detect the association between different HPV genotypes, level of induced protein 10 (IP-10) and the clinical response to Candida antigen immunotherapy. Methodology: A cross-section study was conducted on 57 patients with resistant warts. All patients were injected with Candida antigen intralesionally at 2-weeks intervals for six treatment sessions. Clinical response was evaluated after 6 sessions. HPV genotyping was performed using real time PCR. Whole blood from patients was incubated with Candida antigen and IP-10 level was measured by ELISA. Results: Among the 57 injected patients, 31 (54.4%), 18 (31.6%), 8 (14%) show complete, partial and no response respectively. The most frequently detected genotype was HPV-39 (7.1 %) from HPV positive samples. Viral genotype had no significant relation (P=0.305) with patients' clinical response. Statistically significant different IP-10 levels (P<0.001) were detected with different clinical responses. In conclusion: HPV genotype has no significant relation with the clinical response to Candida antigen immunotherapy in wart patients. IP-10 level is an excellent predictive factor for the immune response and hence for the clinical response in those patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.